Characterization and assessment of the sensitivity and resistance of a newly established human gastrointestinal stromal tumour xenograft model to treatment with tyrosine kinase inhibitors

Conclusions: We established a novel human GIST xenograft, UZLX-GIST9, harbouring KIT exon 11 and 17 mutations and maintaining the pheno-and genotype of the original tumour. UZLX-GIST9 shows different levels of response to standard TKIs. This model will help to study TKI resistance and to explore novel treatment approaches for patients with TKI-resistant GIST.

http://www.clinicalsarcomaresearch.com/content/4/1/10

Source: Epidemiologic Perspectives and Innovations - August 10, 2014 Category: Epidemiology Authors: Thomas van LooyYemarshet Kelemework GebreyohannesAgnieszka WozniakJasmien CornillieJasmien WellensHaifu LiUlla VanleeuwGiuseppe FlorisMaria Debiec-RychterRaf SciotPatrick Schöffski Source Type: research